Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | GNA15 | P30679 | 1/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8694026 | 0.98 | FFAR1 (0.67) | FFAR1SRD5A2NR3C1AKR1B1PTGDR2 | |
| Methane SCHEMBL27637860 | 0.96 | FFAR1 (0.65) | FFAR1SRD5A2NR3C1AKR1B1PTGDR2 | |
| SCHEMBL1421946 | 0.89 | PPARG (0.61) | FFAR1SRD5A2NR3C1PTGDR2FFAR4 | |
| SCHEMBL3511533 | 0.87 | FFAR1 (0.59) | FFAR1SRD5A2FFAR4 | |
| SCHEMBL7911502 | 0.87 | FFAR1 (0.59) | FFAR1SRD5A2NR3C1FFAR4GNA15 | |
| SCHEMBL8784786 | 0.86 | CTBP2 (0.60) | FFAR1PTGDR2FFAR4FAAHAKR1C3 | |
| SCHEMBL24677897 | 0.86 | FFAR1 (0.54) | FFAR1SRD5A2NR3C1PTGDR2FFAR4 | |
| SCHEMBL7911513 | 0.86 | PLA2G4B (0.67) | FFAR1SRD5A2NR3C1FFAR4 | |
| SCHEMBL8694023 | 0.86 | FFAR1 (0.54) | FFAR1FFAR4FAAHAKR1C3GNA15 | |
| SCHEMBL10706227 | 0.86 | FFAR1 (0.54) | FFAR1FFAR4FAAHAKR1C3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-0868535-B9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2007-05-09 | — | — | EP | claimed |
| EP-0868535-B2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2006-01-04 | — | — | EP | claimed |
| CN-1163619-C | Method and compositions for determining sequence of nucleic acid molecules | �Ѹ�������ѧ��˾ | 2004-08-25 | — | — | CN | claimed |
| US-20040115694-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | QIAGEN GENOMICS, INC. | 2004-06-17 | — | — | US | claimed |
| EP-0990047-B1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | QIAGEN GENOMICS INC (US) | 2003-05-14 | — | — | EP | claimed |
| US-20030077595-A1 | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays | QIAGEN GENOMICS, INC. | 2003-04-24 | — | — | US | claimed |
| EP-0868535-B1 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE INC (US) | 2000-04-12 | — | — | EP | claimed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| CN-1212021-A | Method and compositions for determining sequence of nucleic acid molecules | RAPIGENE INC (US) | 1999-03-24 | — | — | CN | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| US-4309421-A | Stabilized parenterally administrable solutions | A. NATTERMANN & CIE. GMBH (DE) | 1982-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | FFAR1 4363/4885SRD5A2 4615/4885NR3C1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.